Risankizumab as maintenance therapy for moderately to severely active Crohn's disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trial

Autor: Marc Ferrante, Remo Panaccione, Filip Baert, Peter Bossuyt, Jean-Frederic Colombel, Silvio Danese, Marla Dubinsky, Brian G Feagan, Tadakazu Hisamatsu, Allen Lim, James O Lindsay, Edward V Loftus, Julián Panés, Laurent Peyrin-Biroulet, Zhihua Ran, David T Rubin, William J Sandborn, Stefan Schreiber, Ezequiel Neimark, Alexandra Song, Kristina Kligys, Yinuo Pang, Valerie Pivorunas, Sofie Berg, W Rachel Duan, Bidan Huang, Jasmina Kalabic, Xiaomei Liao, Anne Robinson, Kori Wallace, Geert D'Haens

Publikováno v: The Lancet, 399(10340), 2031-2046. Elsevier Limited

Background: There is a great unmet need for new therapeutics with novel mechanisms of action for patients with Crohn's disease. The ADVANCE and MOTIVATE studies showed that intravenous risankizumab, a selective p19 anti-interleukin (IL)-23 antibody,

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::56e49b5f7038521294b69cf744c4fbd1
https://pure.amc.nl/en/publications/risankizumab-as-maintenance-therapy-for-moderately-to-severely-active-crohns-disease(a545e349-2239-4e02-8ea2-d744c64bcc91).html

Long-Term Safety and Efficacy of Risankizumab Treatment in Patients with Crohn's Disease: Results from the Phase 2 Open-Label Extension Study

Autor: Marc Ferrante, Arthur Kaser, Geert R. D'Haens, Wan-Ju Lee, Julián Panés, Xiaomei Liao, Olivier Dewit, Brian G. Feagan, Filip Baert, Jasmina Kalabic, W. Rachel Duan, Kori Wallace, Yinuo Pang, Dawn Gustafson, Edouard Louis

Publikováno v: Journal of Crohn's & colitis, 15(12), 2001-2010. Elsevier
Journal of Crohn's & colitis, Vol. 15, no.12, p. 2001-2010 (2021)
Journal of Crohn's & Colitis

Background and Aims Risankizumab, an interleukin-23 antibody, demonstrated efficacy and acceptable safety in a phase 2 study of patients with moderate-to-severe refractory Crohn’s disease. This open-label extension investigated the long-term safety

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1e418780af15ef3e836bc2ac0db175f7
https://pure.amc.nl/en/publications/longterm-safety-and-efficacy-of-risankizumab-treatment-in-patients-with-crohns-disease(2efdb272-1af3-47e5-a541-ad43af36fa8f).html

Elagolix Alone or With Add-Back Therapy in Women With Heavy Menstrual Bleeding and Uterine Leiomyomas

Autor: Charlotte D. Owens, Nelson B. Watts, Ahmed M. Soliman, Matthew B. Dufek, Michael P. Diamond, Ayman Al-Hendy, W. Rachel Duan, David F. Archer, Jingjing Gao, Linda D. Bradley, Bruce R. Carr, Elizabeth A. Stewart, James A. Simon, Kristof Chwalisz

Publikováno v: Obstet Gynecol

To evaluate elagolix, an oral gonadotropin-releasing hormone receptor antagonist, alone or with add-back therapy, in premenopausal women with heavy menstrual bleeding (greater than 80 mL per month) associated with uterine leiomyomas.This double-blind

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4a4ce471aba925c74f326004566e2e0d
https://doi.org/10.1097/aog.0000000000002933

Long-Term Outcomes of Elagolix in Women With Endometriosis: Results From Two Extension Studies

Autor: Paul M Peloso, Mauricio Simões Abrão, Kristof Chwalisz, Sanjay K. Agarwal, Eric S. Surrey, Bruce R. Carr, Bruce A. Lessey, J. Chris Gallagher, B. Schwefel, W. Rachel Duan, Tomasz Rechberger, Juki Ng, Ahmed M. Soliman, Sukhbir Singh, Linda C. Giudice, Neil P. Johnson, James W Thomas, Hugh S. Taylor, Michael P. Diamond, Nicholas Leyland, Nelson B. Watts, David F. Archer, W. Paul Dmowski, James A. Simon

Publikováno v: Obstetrics and gynecology. 132(1)

To evaluate the efficacy and safety of elagolix, an oral, nonpeptide gonadotropin-releasing hormone antagonist, over 12 months in women with endometriosis-associated pain.Elaris Endometriosis (EM)-III and -IV were extension studies that evaluated an

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d23877fa99f7b08ba8092bc3f93bcdb9
https://pubmed.ncbi.nlm.nih.gov/30461685

An oral TRPV1 antagonist attenuates laser radiant-heat-evoked potentials and pain ratings from UVB-inflamed and normal skin

Autor: Charles Locke, Peter W. Reeh, W. Rachel Duan, Ahmed A. Othman, Klaus Schaffler, Connie R. Faltynek, Wolfram Nothaft, Andrea E. Best

Publikováno v: British Journal of Clinical Pharmacology. 75:404-414

Aims Laser (radiant-heat) evoked potentials (LEPs) from vertex-EEG peak-to-peak (PtP) amplitude were used to determine acute antinociceptive/antihyperalgesic efficacy of ABT-102, a novel TRPV1 antagonist efficacious in preclinical pain models, compar

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::c3512370321050a2147fbafccf5e6a4c
https://doi.org/10.1111/j.1365-2125.2012.04377.x